BTC Health Limited (ASX:BTC) Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from Pharmaxis
Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from PharmaxisMelbourne, July 6, 2021 AEST (ABN Newswire) - BTC Health Limited (
ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (
ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).
The exclusive distribution agreement is effective 1 July 2021, with an initial term of 10 years and automatic renewals for subsequent 3-year terms. Pharmaxis will continue to manufacture and supply Bronchitol(R) and Aridol(R) to BTC health from its TGA approved facility in Sydney. As financial consideration for the distribution rights, BioImpact Pty Ltd will make a once-off payment of $2m to Pharmaxis within 10 bus